Public Company Information:
RICHMOND Va. & LONDON & SYDNEY--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation [APHB.PK] (“Ampliphi”)(OTCBB:APHB), the anti-infective company focused on developing phage-based therapies to combat the growing threat of antibiotic-resistant infection, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 13/333,684 entitled “Bacteriophage-Containing Therapeutic Agents”.
The patent application is important to Ampliphi’s patent estate and developing portfolio, as it covers the use of bacteriophage-based therapy for the treatment of infections caused by the bacteria Pseudomonas aeruginosa associated with biofilms in effective combination with antibiotics. Examples of specific treatment regimens covered include the treatment of human and animal infections resulting from a skin burn or skin wound, a lung infection, an eye, ear or urinary infection or an infection associated with a medical device or implant. Such infections are difficult to treat as they are often resistant to treatment with currently available antibiotics using standard methods of treatment.
The U.S. Patent Application No. 13/333,684 includes claims intended to protect the Company’s method of treating bacterial infection characterized by biofilm where P. aeruginosa is present, covering the application of one or more bacteriophage preparations that have one or multiple treatments which target and kill P. aeruginosa in the biofilm, at least 24 hours before antibiotic treatment.
Phil Young, CEO of Ampliphi said: “Our nonclinical results have indicated that treatment with our bacteriophage preparations before antibiotics are administered can restore the effectiveness of antibiotics that were previously ineffective”. He continued “Such a treatment regime could be enormously important in the battle to address the rise of antibiotic resistance and, in particular to treat infections present in biofilms.”
The Company’s lead program, a proprietary mix of bacteriophages, is in late preclinical development for the treatment of P. aeruginosa infection of the lung, aimed at patients with Cystic Fibrosis (CF). Biofilms are a major element in infection of the CF lung.
Bacteriophages are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophages are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defence for bacteria, contributing to antibiotic resistance. Bacteriophages are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.
The corresponding patent has already been issued in Australia as patent number 2004258731, issued 10th June 2010 with patent applications undergoing examination in Europe, Canada and Japan. Ampliphi is committed to protecting its novel therapeutics in key jurisdictions. Further patent applications are under examination, supporting AmpliPhi’s work in building a strong intellectual property portfolio around its technology and strengthening its leadership position in the field of bacteriophage based therapies.
AmpliPhi‘s strategy is to develop a targeted pipeline of therapeutics in-house and to secure collaborations with third parties to maximise the potential of its innovative bacteriophage platform technology.
– Ends –
Notes to editors
AmpliPhi Biosciences Corporation [APHB.PK], created in 2011 through the merger of Biocontrol Limited with Targeted Genetics Inc., and subsequent combination with Special Phage Services in 2012, is a biotechnology company dedicated to the development of innovative antibacterial solutions to improve human and animal health through the application of its proprietary bacteriophage platform. The Company’s lead product development programs are targeting Gram-negative infections that are often resistant to existing antibiotic treatments. For more information, please visit www.ampliphibio.com
This press release contains certain forward-looking statements that involve known and unknown risks, delays, uncertainties, and other factors not under the control of the Ampliphi. Ampliphi’s actual results, performance, or achievements may differ materially from those conveyed in such forward-looking statements, and Ampliphi disclaims any intent or obligation to update these forward-looking statements. Examples of such forward looking statements include, but are not limited to, statements about: the potential research and development programs of Ampliphi; potential therapies and target indications in both humans and animals that the Company may research and develop; and the scope and benefits of Ampliphi’s patents. The factors that could cause actual results, performance or achievements to differ from the forward-looking statements include the risk that Ampliphi’s current financial resources and future financial resources will be insufficient to enable Ampliphi to fund continuing operations; difficulties or delays in obtaining financing or in entering partnering transactions; and the risk that Ampliphi’s product research, development and commercialization efforts will be unsuccessful. Ampliphi is not subject to the reporting obligations of the Securities and Exchange Act of 1934 and, accordingly, is not required to file current or periodic reports with the Securities and Exchange Commission.
At the Company
Phil Young, CEO
Media enquires – College Hill Life Sciences
Sue Charles - Managing Partner - Global
+44 (0)7968 726585 (UK)
+61 (0)466 924218 (AUS)
+1 347 448 3210 (USA)
Gemma Howe/Stefanie Bacher - UK
+44 20 7457 2020
Dr Douglas Pretsell – AUS
+61 (0)466 925 966